Aleix Prat, MD, PhD
Women with the HER2-enriched subtype of early-stage, HER2-positive breast cancer were more likely to have a pathological complete response (pCR) when treated with dual HER2-blockade, according to results from the PAMELA trial published in The Lancet Oncology
He went on to say that researchers are also trying to understand why most women with the HER2-enriched subtype (59%) did not respond strongly to the HER2 blockade. “We know there is still biological heterogeneity even within a subtype. For example, a subset of HER2-enriched tumors has PIK3CA mutations, a potential biomarker of response. Thus, we are currently working on analyzing this biological heterogeneity within HER2-enriched to identify additional biomarkers of response beyond subtype.”
From October 2013 to November 2015, researchers for the PAMELA trial recruited 151 women at 19 hospitals in Spain. All patients were diagnosed with previously untreated, centrally confirmed HER2-positive, stage I to IIIA invasive breast cancer.
... to read the full story